Research programme: immune cell therapeutics - Cellect Biotechnology
Latest Information Update: 17 Jan 2017
At a glance
- Originator Cellect Biotechnology
- Class Cell therapies
- Mechanism of Action Cell replacements; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders